drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Gene-modified natural killer T cells engineered to express a chimeric antigen receptor targeting CD70; infused after lymphodepleting chemotherapy to treat CD70-positive advanced solid tumors via largely MHC-independent cytotoxicity and cytokine release.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptors
drug_category
OTHER ENGINEERED IMMUNE CELL
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous natural killer T cells engineered to express a CD70-specific chimeric antigen receptor bind CD70 on tumor cells and, upon CAR activation, execute largely MHC-independent killing via perforin/granzyme release and pro-inflammatory cytokine secretion; lymphodepleting cyclophosphamide/fludarabine is used to enhance engraftment and expansion.
drug_name
CGC729 (CD70-targeted CAR-NKT cells)
nct_id_drug_ref
NCT06394622